McCune-Albright Syndrome Clinical Trial
Official title:
An Open-label Study Evaluating the Safety and Efficacy of Anastrozoleā¢ (ARIMIDEX) in the Treatment of Precocious Puberty in Girls With McCune-Albright Syndrome
The primary objective of this study is to evaluate the safety and efficacy of anastrozole 1 mg given once daily in subjects with McCune-Albright Syndrome.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00278915 -
Faslodex in McCune-Albright Syndrome
|
Phase 2 | |
Recruiting |
NCT00001727 -
Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome
|
||
Withdrawn |
NCT03520153 -
Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome
|
||
Completed |
NCT00318097 -
Histamine Responsiveness in McCune-Albright Syndrome
|
N/A |